Minerva Neurosciences | NERV - Cash And Equivalent

Minerva Neurosciences reported $36.09M in Cash and Equivalent for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US USD 114.85M 40M
Adma Biologics ADMA:US USD 86.52M 51.62M
ALKERMES ALKS:US USD 740.08M 476.12M
AstraZeneca AZN:LN USD 6.17B 1.71B
Biocryst Pharmaceuticals BCRX:US USD 304.77M 156.42M
Bristol Myers Squibb BMY:US USD 9.12B 1.39B
Dynavax Technologies DVAX:US USD 202M 3.43M
Esperion Therapeutics ESPR:US USD 124.78M 34.62M
GlaxoSmithKline GSK:LN GBP 3.72B 117M
Halozyme Therapeutics HALO:US USD 234.2M 87.04M
IONIS PHARMACEUT IONS:US USD 276.47M 38.52M
Marinus Pharmaceuticals MRNS:US USD 240.55M 72.3M
Minerva Neurosciences NERV:US USD 36.09M 4.13M
Neurocrine Biosciences NBIX:US USD 262.9M 50.7M
Novartis NOVN:VX USD 7.52B 1.21B
Novavax NVAX:US USD 1.34B 56.3M
Roche Holding ROG:VX 4.99B 676M
Takeda 4502:JP JPY 685.14B 113B
Vanda Pharmaceuticals VNDA:US USD 135.03M 85.63M